Slingshot members are tracking this event:

Merck’s KEYTRUDA (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 02, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Keytruda, Pembrolizumab, European Commission, Advanced Non-small Cell Lung Cancer, Nsclc, Tumor, Pd-l1, Keynote-010, Chemotherapy